The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Name: The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
Published: 2024
License: Public Domain

Telix Pharmaceuticals (Innovations) Pty Limited · 2024

ClinicalTrials.gov · Datasets · License: Public Domain · 2024

Open Source ↗

overall-survival prostate-cancer

metastatic castration-resistant prostate cancer, radiographic progression free survival, overall survival, arpi, docetaxel, prostate cancer, radionuclide therapy, tlx591, prostact global, psma- targeting agent, mcrpc, 177lu-tlx591

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 902826
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.